8月18日 - ** 疗法开发商Soligenix SNGX.O股价盘前上涨47.5%至4.08美元
** 公司称美国食品及药物管理局在对中期研究数据进行审查后，已授予其治疗白塞氏病的 "孤儿药 "标签
** 公司正在轻中度白塞氏病患者中测试 SGX945 的活性成分 dusquetide
** 白塞氏病是一种罕见的炎症性疾病，可影响身体的多个部位，最主要的是引起口腔和生殖器疼痛性溃疡以及眼部炎症
** 美国食品和药物管理局（FDA）授予孤儿药资格，以促进影响美国少于 20 万人的罕见疾病的药物开发。
** 截至上次收盘，该股今年累计上涨 3.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.